This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celanese's CEO Discusses Q2 2012 Results - Earnings Call Transcript

We plan to use this process going forward to provide more time to analyze the results before we take your questions. If you have suggestions to further improve the process, please let me know.

Before I get to results, I expect many of you have questions about our contractual relationship with Southern Chemical Corporation for the procurement of methanol in the U.S. Unfortunately, since we are in active litigation with Southern, and our contract contains confidentiality provisions, we will not be able to answer any questions related to this contract or the litigation today.

Now for the results, we reported the second highest adjusted earnings per share in our history at $1.47, amid a challenging economic environment in Europe, slower growth in Asia and a headwind from currency translation, it was in the high single digit range. Our ability to deliver these results demonstrates the strength of our technology and our portfolio as well as the hard work for the team around the globe. Most noteworthy each business generated strong sequential earnings growth pushing operating EBITDA to the $404 million range or 24% of sales. In fact Industrial Specialties set a quarterly earnings record of $47 million and on a year-over-year basis our three specialty businesses increased operating EBITDA by approximately 12%.

Acetyl Intermediates earnings declined in the second quarter primarily due to a difficult year-over-year comparison. It was driven by temporarily elevated industrial utilizations in the prior year. Within this quarter AI experienced trough-like levels of operating EBITDA due to weak economic conditions in Europe and slow growth in Asia impacting demand and pricing. At quarter’s end, we believe industry utilization rates were in the mid 70% range with Asian utilization rates closer to 50%. Yet even in this environment the company generated $1.04 per share of adjusted earnings excluding the dividend from the Acetate ventures.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs